The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000499381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/03/2026
Date registered
Help: Date registered
22/04/2026
Date last updated
Help: Date last updated
22/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
22/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
MethoxyFLurane inhaler for single episode cancer-related incident pain in palliative cARE patients: The FLARE feasibility study
Scientific title
MethoxyFLurane inhaler for single episode cancer-related incident pain in palliative cARE patients: The FLARE feasibility study
Additional trial identifiers [1] 316703 0
BH101
Universal Trial Number (UTN)
Trial acronym
The FLARE
Related trial records

Health condition
Health condition(s) studied:
Advanced cancer 340957 0
Incidental Cancer Pain 340959 0
Condition category
Condition code
Cancer 337106 337106 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
evaluating methoxyflurane as an acceptable alternative to standard care in managing single episode Incidental Cancer Pain in palliative care.
Each participant will be given one inhaler loaded with one dose (3 mL) of methoxyflurane. If the participant continues to experience clinically significant pain during the same procedure after the first dose, a second dose (3 mL) may be provided, at the discretion of the supervising healthcare practitioner (HCP). Any second dose will be administered only during the same procedure, after the first inhaler has been used, with a maximum total dose of 6 mL for that procedure. All participants will be under the supervision of an HCP appropriately trained in the administration technique. The trained HCP will assist the participant with the self-administration of methoxyflurane inhaler for the duration of the procedure.
Intervention code [1] 333385 0
Treatment: Drugs
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344622 0
To determine the feasibility of studying methoxyflurane for single episode Incident cancer pain in an Australian palliative care population
Timepoint [1] 344622 0
12 months post-first enrolment
Secondary outcome [1] 458671 0
To evaluate the efficacy of methoxyflurane as an analgesic agent for single episode IcP.
Timepoint [1] 458671 0
12 Months post-first enrolment
Secondary outcome [2] 458672 0
To assess the tolerability and safety of methoxyflurane which will be will be assessed together as a composite secondary outcome
Timepoint [2] 458672 0
12 Months post-first enrolment
Secondary outcome [3] 458673 0
Requirement for additional breakthrough analgesic therapy following methoxyflurane administration
Timepoint [3] 458673 0
12 Months post-first enrolment

Eligibility
Key inclusion criteria
Adult patients with advanced cancer who are known to a palliative care service and meet the pre-specified inclusion and exclusion criteria. Patients will be scheduled to undergo a procedure/event considered likely by clinical staff to induce IcP and require the use of a rapid onset/offset analgesic agent. Potential examples include radiotherapy, malignant wound dressing, or personal hygiene activities. • Age 18 years or older.
• Diagnosis of advanced cancer.
• Known to a palliative care service.
• Undergoing a procedure felt by clinical staff likely to induce IcP requiring the use of a rapid onset/offset analgesic agent.
• Capacity to provide written informed consent.
• Be able to use a methoxyflurane inhaler device.
• Have had a recent measurement of renal and liver function within the preceding two weeks (or be able to undergo venipuncture for this purpose).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Clinically significant cardiac or respiratory disease, where associated with cardiovascular instability or respiratory depression.
• Personal or family history of adverse reactions to methoxyflurane (or any volatile anaesthetic).
• Personal or family history of malignant hyperthermia.
• Altered consciousness defined as Glascow Coma Scale < 13.
• Impaired renal function (defined as eGFR <45), or receiving nephrotoxic antibiotics (e.g. tetracycline, gentamicin, colistin, polymyxin B or amphotericin B).
• Liver disease resulting in AST/ALT elevation above 3 times the upper limit of normal (ULN), or elevation of bilirubin above 2 times the upper limit of normal (unless hyperbilirubinaemia is explained by a diagnosis of Gilbert's syndrome).
• Taking CYP-450 enzyme inducers (e.g. alcohol, isoniazid, phenobarbital or rifampicin).
• Dosing expected to exceed the acceptable dosing of Methoxyflurane (no more than two ampules,3mL each, per episode).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321308 0
Other Collaborative groups
Name [1] 321308 0
ReVITALISE (Regional Victorian Trials Alliance: Linkages, Innovation, Special populations, Equity)Project
Country [1] 321308 0
Australia
Primary sponsor type
Government body
Name
Latrobe Regional Health
Address
Country
Australia
Secondary sponsor category [1] 324039 0
None
Name [1] 324039 0
Address [1] 324039 0
Country [1] 324039 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319840 0
Peter MacCallum Cancer Centre Human Research Ethics Committee
Ethics committee address [1] 319840 0
Ethics committee country [1] 319840 0
Australia
Date submitted for ethics approval [1] 319840 0
Approval date [1] 319840 0
03/09/2025
Ethics approval number [1] 319840 0
HREC/119112/PMCC

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148578 0
Dr Ahmed Nagla
Address 148578 0
Latrobe Regional Health, 10 Village Ave, Traralgon VIC 3844
Country 148578 0
Australia
Phone 148578 0
+613 5173 8713
Fax 148578 0
Email 148578 0
Contact person for public queries
Name 148579 0
Ahmed Nagla
Address 148579 0
Latrobe Regional Health, 10 Village Ave, Traralgon VIC 3844
Country 148579 0
Australia
Phone 148579 0
+61 351738713
Fax 148579 0
Email 148579 0
Contact person for scientific queries
Name 148580 0
Ahmed Nagla
Address 148580 0
Latrobe Regional Health, 10 Village Ave, Traralgon VIC 3844
Country 148580 0
Australia
Phone 148580 0
+61 351738713
Fax 148580 0
Email 148580 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    25_101 Ethical Approval Certificate 03Sept2025.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.